Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects

European Journal of Clinical Pharmacology

Volumn 50, Issue 1-2, 1996, Pages 47-55

  Dingemanse, J ^a   Jorga, K ^a   Zurcher G ^a   Fotteler, B ^a   Sedek, G ^a   Nielsen, T ^a   Van Brummelen, P ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Elderly; levodopa; Multiple dose; Pharmacodynamics; Pharmacokinetics; Tolcapone

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; TOLCAPONE;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TOLERABILITY; DRUG TOLERANCE; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO; VOLUNTEER; VOMITING;

AGED; BENZOPHENONES; BIOTRANSFORMATION; CATECHOL O-METHYLTRANSFERASE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; ERYTHROCYTES; FEMALE; HALF-LIFE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITROPHENOLS;

EID: 0030005858     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050068     Document Type: Article

References (26)

1. Coleman RJ (1992) Current drug therapy for Parkinson's disease. A review. Drugs Aging 2:112-124
2. Crome P, Patterson LJ (1989) Drugs and the elderly: adverse reactions, abuse and overdosage. In: Turner P, Volans GN (eds) Recent advances in clinical pharmacology and toxicology. Churchill Livingstone, London, pp 159-172
3. Dingemanse J, Danhof M, Breimer DD (1988) Pharmacokinetic pharmacodynamic modelling of CNS drug effects. An overview. Pharmacol Ther 38:1-52
4. Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Zürcher G, Da Prada M, van Brummelen P (1995a) Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 57:508-517
5. Dingemanse J, Jorga K, Zürcher G, Schmitt M, Sedek G, Da Prada M, van Brummelen P (1995b) Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 40:253-262
6. Evans MA, Broe GA, Triggs EJ, Cheung M, Creasey M, Paull PD (1981) Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology 31:1288-1294
7. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York
8. Guldberg HC, Marsden CD (1975) Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol Rev 27:135-206
9. Holford NHG, Sheiner LB (1981) Pharmacokinetic and pharmacodynamic modeling in vivo. CRC Critical Reviews in Bioengineering 5:273-322
10. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (1993) The fifth report of the joint national committee on detection, evaluation, and treatment of high blood pressure (JNC V). Arch Int Med 153:154-183
11. Kaakkola S, Gordin A, Järvinen M, Wikberg T, Schultz E, Nissinen E, Pentikäinen PJ, Rita H (1990) Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin Neuropharmacol 13:436-447
12. Kaakkola S, Gordin A, Männistö PK (1994) General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen Pharmacol 25:813-824
13. Keränen T, Gordin A, Harjola V-P, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, Seppälä L, Wikberg T (1993) The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16:145-156
14. LeWitt PA (1989) The pharmacology of levodopa in treatment of Parkinson's disease: an update. In: Calne DB (ed) Handbook of experimental pharmacology, vol 88. Springer, Berlin Heidelberg New York, pp 325-384
15. Limousin P, Pollak P, Pfefen JP, Tournier-Gervason CL, Dubuis R, Perret JE (1995) Acute administration of levodopabenserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin Neuropharmacol 18:258-265
16. Männistö PT (1994) Clinical potential of catechol-O-methyltransferase (COMT) inhibitors as adjuvants in Parkinson's disease. CNS Drugs 1:172-179
17. Marsden CD (1994) Parkinson's disease. J Neurol Neurosurg Psychiatry 57:672-681
18. Mizuno Y, Mori H, Kondo T (1994) Practical guidelines for the drug treatment of Parkinson's disease. CNS Drugs 1:410-426
19. Nohta H, Noma S, Ohkura Y, Yoo B-T (1984) Assay for catechol-O-methyltransferase in erythrocytes using a new fluorogenic substrate, 2-(3,4-dihydroxyphenyl)naphtho(1,2-d)thiazole. J Chromatogr 308:93-100
20. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, Gancher ST, Hammerstad JP, Gordin A (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44:913-919
21. Rochon PA, Gurwitz JH (1995) Geriatrics septet: drug therapy. Lancet 346:32-36
22. Timm U, Erdin R (1992) Determination of the catechol-O-methyltransferase inhibitor Ro 40-7592 in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr 593:63-68
23. Tolosa ES, Valldeoriola F, Martí MJ (1994) New and emerging strategies for improving levodopa treatment. Neurology 44 (Suppl 6):35-44
24. Zürcher G, Da Prada M (1990) Simple automated high-performance liquid chromatographic column-switching technique for the measurement of dopa and 3-O-methyldopa in plasma. J Chromatogr Biomed Appl 530:253-262
25. Zürcher G, Keller HH, Kettler R, Borgulya J, Bonetti EP, Eigenmann R, Da Prada M (1990) Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH (eds) Advances in neurology, vol 53, Parkinson's disease: anatomy, pathology, and therapy. Raven Press, New York, pp 497-503
26. Zürcher G, Dingemanse J, Da Prada M (1991) Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. In: Agnoli A, Campanella G (eds) New developments in therapy of Parkinson's disease. John Libbey CIC s.r.l., Rome, pp 37-43